

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Steven Edward Coutré, M.D.	POSITION TITLE Professor of Medicine		
eRA COMMONS USER NAME			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Northwestern University, Evanston, Illinois	B.A.	1981	Biochemistry
Stanford University School of Medicine, Stanford, CA	M.D.	1986	Medicine
Yale-New Haven Hospital, New Haven, Connecticut		1986-1989	Residency
Division of Hematology, Stanford University School of Medicine, Stanford, CA		1989-1992	Fellowship
Dept. of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA			

A. Personal Statement

Dr. Coutre is interested in the development of novel therapies for hematologic malignancies including chronic lymphocytic leukemia and multiple myeloma. He is the principal investigator on numerous phase I-III clinical trials for patients with hematologic malignancies including investigator-initiated, national cooperative group, and industry-sponsored trials.

B. Positions and Honors**Positions and Employment**

1992-1994 Research Scientist, Preclinical Development
Vascular Biology and Medicine, Gilead Sciences, Foster City, California

1994-1995 Physician in private practice, Deerpath Medical Associates
Lake Forest Hospital, Lake Bluff, Illinois

1995-1996 Acting Assistant Professor of Medicine (Hematology), Stanford University

1996-2004 Assistant Professor of Medicine (Hematology), Stanford University

2004-2013 Associate Professor of Medicine (Hematology), Stanford University

2011-2014 Vice Chair, Clinical Affairs, Department of Medicine, Stanford University

2013- Professor of Medicine (Hematology), Stanford University

Honors & Awards

1981 Honors in Biochemistry and Molecular Biology

1983 Stanford Alumni Medical Student Scholarship

1990 Research Honors Award

1996 Timothy F. Beckett, Jr. Award for Excellence in Clinical Teaching

2002 Division Teaching Award, Stanford University School of Medicine

Professional Memberships

1994- American Society of Hematology

2014-present Committee on Practice, American Society of Hematology

1995- Southwest Oncology Group (Leukemia Committee)

2012- Southwest Oncology Group, Vice Chair (Leukemia Committee)

1998- National Comprehensive Cancer Network (Acute Myelogenous Leukemia Panel)

2011- National Comprehensive Cancer Network (Acute Lymphoblastic Leukemia Panel)

C. Selected peer-reviewed publications (in chronological order) (Selected from >85 publications)

1. Gibbs CS, **Coutré S**, Tsiang M, Li W-X, Jain AK, Dunn KE, Law VS, Mao CT, Matsumura SY, Mejza SJ, Paborsky LR, Leung LLK; Conversion of thrombin into an anticoagulant by protein engineering; *Nature*; 378:413-16, 1995. PMID: 7477382
2. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, **Coutré S**, Dahlberg S, Ellison R, Warrell RP Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. *J Clin Oncol*; 19(18):3852-60, 2001. PMID: 11559723
3. Keating MJ, Cazin B, **Coutré S**, Bhiriray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjonnfjord G, Bekradda M, Itzhaki M, Herait. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. *J Clin Oncol*; 20(1):205-13, 2002. PMID: 11773171
4. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, **Coutré S**, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. *Blood*; 99(10):3530-9, 2002. PMID: 11986204
5. Cools J, DeAngelo D, Gotlib J, Stover EH, Legare RD, Malone J, Kutok J, Boulton CL, Williams I, Clark J, Galinsky I, Griffin JD, Cross NP, Tefferi A, Alam R, Cortes J, Kantarjian H, Schrier SL, Schmid J, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Marynen P, **Coutré SE**, Stone RD, and Gilliland DG. A novel tyrosine kinase created by fusion of the *PDGFRA* and *FIP1L1* genes represents the therapeutic target of imatinib in idiopathic hypereosinophilic syndromes. *New Engl J Med*; 348:1201-14, 2003. PMID: 12660384.
6. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, **Coutré SE**, Stone RM, DeAngelo DJ, Marynen P, Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, Griffin JD, and Gilliland DG. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR α -induced myeloproliferative disease. *Cancer Cell*; 3:459-69, 2003. PMID: 12781364
7. Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, and **Coutré SE**. The FIP1L1-PDGFR α fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. *Blood*; 103:2879-91, 2004. PMID: 15070659
8. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, **Coutré SE**. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. *Blood*; 106:2865-70, 2005. PMID: PMC1895309
9. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlag N, **Coutré S**, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. *Blood*, 109:3207-13, 2007. PMID: 17185463
10. Deangelo DJ, Yu D, Johnson JL, **Coutré SE**, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801. *Blood*, 109:5136-42, 2007. PMID: PMC1941786
11. Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, **Coutré SE**, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P. International Standardized Approach for Flow Cytometric Residual Disease Monitoring in Chronic Lymphocytic Leukemia. *Leukemia*; 21:956-64, 2007. PMID: 17361231
12. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, Gollerkeri A, **Coutré S**. Dasatinib Induces Rapid Hematologic and

- Cytogenetic Responses in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia with Resistance or Intolerance to Imatinib: Interim Results of a Phase 2 Study. *Blood*; 110:2309-15, 2007. PMID: 17496201
13. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, **Coutre S**, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and over-all survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. *Blood*; 116:3751-7, 2010. PMCID: PMC2981533
 14. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, **Coutre S**, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Jedrzejczak WW, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. *Blood*; 117:3294-301, 2010. PMCID: PMC3069671
 15. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, **Coutre S**, Chao MP, Chen L, Tedder TF, Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. *Blood*; 117:2423-32, 2011. PMCID: PMC3062409
 16. Kreitman RJ, Tallman MS, Robak T, **Coutre S**, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Lechleider R, and Pastan I. Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients with Hairy Cell Leukemia. *J Clin Oncol*; 30:1822-8, 2012. PMCID: PMC3383181
 17. Byrd JC, Furman RR, **Coutre SE**, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, and O'Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *N Engl J Med*; 369:32-42, 2013. PMID: 23782158
 18. O'Brien S, Furman RR, **Coutre SE**, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, and Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. *Lancet Oncol*; 15:48-58, 2014. PMID: 24332241
 19. Furman RR, Sharman JP, **Coutre SE**, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, and O'Brien SM. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. *N Engl J Med*; 370:997-1007, 2014. PMID: 24450857
 20. **Coutre SE**, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, and Appelbaum FR. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. *Br J Haematol*; 165:497-503, 2014. PMID: 24528179
 21. Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, and Spurgeon SE. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- δ , as therapy for previously treated indolent non-Hodgkin lymphoma. *Blood*; 123:3406-13, 2014. PMID:24615776
 22. Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND. A phase 1 study of the PI3K δ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). *Blood*; 123:3398-405, 2014. PMID:24615778
 23. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman H, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, and Furman RR. Idelalisib, an Inhibitor of Phosphatidylinositol 3 Kinase p110 δ , for Relapsed/Refractory Chronic Lymphocytic Leukemia. *Blood*; 123:3390-7, 2014. PMID:24615777

24. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, **Coutre S**, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreiv J, Clow F, James DF, and Hillmen P; the RESONATE Investigators. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. *N Engl J Med*; 2014;371(3):213-23. PMID: 24881631
25. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, **Coutre S**, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ, Investigators R-. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. *N Engl J Med*; 2015;373(25):2425-37. PMID: 26639149
26. Byrd JC, Furman RR, **Coutre SE**, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. *Blood*; 2015;125(16):2497-506. PMID: 25700432
27. O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, **Coutre SE**. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. *Blood*; 2015;126(25):2686-94. PMID: 26472751

D. Research Support (selected current studies)

Celgene Corporation	Coutre (PI)	05/11/09-12/31/16
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) As Maintenance Therapy For Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy Protocol CC-5013-CLL-002. Role: Principal investigator for a multi-site trial at the Stanford site		
Gilead Sciences	Coutre (PI)	02/01/10-12/31/16
A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of CAL-101 in Combination with Rituximab in Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Role: Co-Investigator for the overall study		
Gilead Sciences	Coutre (PI)	09/10/12-07/31/20
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia. Role: Co-Investigator for the overall study		
Gilead Sciences	Coutre (PI)	06/04/12-05/31/17
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia. Role: Co-Investigator for the overall study		
Pharmacyclis	Coutre (PI)	11/13/12-08/31/17
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Role: Co-Investigator for the overall study		
Pharmacyclis	Coutre (PI)	01/28/13-06/30/16
An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion. Role: Co-Investigator for the overall study		
Pharmacyclis	Coutre (PI)	07/18/13-06/30/16
PCYC-1115-CA: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Role: Co-Investigator for the overall study		
AbbVie	Coutre (PI)	11/01/13-10/31/16

